Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
44%(4 trials)

Phase Distribution

Ph phase_1
2
20%
Ph phase_2
3
30%
Ph phase_3
5
50%

Phase Distribution

2

Early Stage

3

Mid Stage

5

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
5(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(9)
Terminated(1)

Detailed Status

Completed9
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (20.0%)
Phase 23 (30.0%)
Phase 35 (50.0%)

Trials by Status

completed990%
withdrawn110%

Recent Activity

0 active trials
Showing 5 of 10
withdrawnphase_1

Ruboxistaurin in New York Heart Failure Classification III-IV Patients

NCT02769611
completedphase_3

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

NCT00090519
completedphase_3

Treatment for Completers of the Study B7A-MC-MBCM

NCT00266695
completedphase_3

Effect of Ruboxistaurin on Clinically Significant Macular Edema

NCT00133952
completedphase_3

Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study

NCT00604383
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT02769611Phase 1

Ruboxistaurin in New York Heart Failure Classification III-IV Patients

Withdrawn
NCT00090519Phase 3

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

Completed
NCT00266695Phase 3

Treatment for Completers of the Study B7A-MC-MBCM

Completed
NCT00133952Phase 3

Effect of Ruboxistaurin on Clinically Significant Macular Edema

Completed
NCT00604383Phase 3

Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study

Completed
NCT00297401Phase 3

Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus

Completed
NCT00190970Phase 2

The Effect of Ruboxistaurin on Small Fiber Function

Completed
NCT00482976Phase 2

Effect of LY333531 on Vascular and Neural Functions

Completed
NCT00552227Phase 1

Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus

Completed
NCT00761852Phase 2

Signaling Mechanisms and Vascular Function in Diabetes Mellitus

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10